Per Boye Hansen1,2, Milena Penkowa3. 1. Department of Hematology, Herlev Hospital, University of Copenhagen, 2720, Herlev, Denmark. pbhn@regionsjaelland.dk. 2. Department of Hematology, University Hospital of Roskilde, DK-4000, Roskilde, Denmark. pbhn@regionsjaelland.dk. 3. Section for Neuroprotection, Hjerneeksperten, 1718, Copenhagen, Denmark.
Abstract
PURPOSE:High-dose chemotherapy prior to autologous stem cell transplantation (ASCT) leads to adverse effects including mucositis, neutropenia and bacteremia. To reduce the toxicity, we treated myeloma and lymphoma patients with peroral bismuth as an adjuvant to chemotherapy to convey cytoprotection in non-malignant cells. METHODS: This trial was a prospective, randomised, double-blind, placebo-controlled pilot study of hematological inpatients (n = 50) receiving bismuth or placebo tablets, in order to identify any potential superiority of bismuth on toxicity from chemotherapy. RESULTS: We show for the first time that bismuth significantly reduces grade 2 stomatitis, febrile neutropenia and infections caused by melphalan in multiple myeloma, where adverse effects also were significantly linked to gender. In lymphoma patients, bismuth significantly reduces diarrhoea relative to placebo. Also, lymphoma patients' adverse effects were linked to gender. For the first time, bismuth is demonstrated as a safe strategy against chemotherapy's toxicity without interfering with intentional anti-cancer efficiency. Also, we show how gender significantly influences various adverse effects and response to treatment in both multiple myeloma and malignant lymphomas. CONCLUSION: These results may impact clinical prevention of chemotherapy's cytotoxicity in certain patient groups, and also, this study may direct further attention towards the impact of gender during the course and treatment outcome of malignant disorders.
RCT Entities:
PURPOSE: High-dose chemotherapy prior to autologous stem cell transplantation (ASCT) leads to adverse effects including mucositis, neutropenia and bacteremia. To reduce the toxicity, we treated myeloma and lymphomapatients with peroral bismuth as an adjuvant to chemotherapy to convey cytoprotection in non-malignant cells. METHODS: This trial was a prospective, randomised, double-blind, placebo-controlled pilot study of hematological inpatients (n = 50) receiving bismuth or placebo tablets, in order to identify any potential superiority of bismuth on toxicity from chemotherapy. RESULTS: We show for the first time that bismuth significantly reduces grade 2 stomatitis, febrile neutropenia and infections caused by melphalan in multiple myeloma, where adverse effects also were significantly linked to gender. In lymphomapatients, bismuth significantly reduces diarrhoea relative to placebo. Also, lymphomapatients' adverse effects were linked to gender. For the first time, bismuth is demonstrated as a safe strategy against chemotherapy's toxicity without interfering with intentional anti-cancer efficiency. Also, we show how gender significantly influences various adverse effects and response to treatment in both multiple myeloma and malignant lymphomas. CONCLUSION: These results may impact clinical prevention of chemotherapy's cytotoxicity in certain patient groups, and also, this study may direct further attention towards the impact of gender during the course and treatment outcome of malignant disorders.
Authors: Samuel Vokurka; Eva Bystrická; Vladimír Koza; Jana Scudlová; Vladislava Pavlicová; Dana Valentová; Jana Bocková; Lubica Misaniová Journal: Support Care Cancer Date: 2005-03-30 Impact factor: 3.603
Authors: Samuel Vokurka; Eva Bystrická; Vladimír Koza; Jana Scudlová; Vladislava Pavlicová; Dana Valentová; Maria Visokaiová; Lubica Misaniová Journal: Support Care Cancer Date: 2006-02-25 Impact factor: 3.603
Authors: A Waśko-Grabowska; P Rzepecki; S Oborska; J Barzał; K Gawroński; B Młot; C Szczylik Journal: Transplant Proc Date: 2011-10 Impact factor: 1.066
Authors: M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: N Blijlevens; M de Château; G Krivan; W Rabitsch; A Szomor; R Pytlik; A Lissmats; H E Johnsen; T de Witte; H Einsele; T Ruutu; D Niederwieser Journal: Bone Marrow Transplant Date: 2012-12-17 Impact factor: 5.483